Friday, July 10, 2026

pharma · Obesity, Overweight · Type 2 Diabetes

Eli Lilly and

Eli Lilly and clinical programs — 21 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Lilly Corporate Center, Indianapolis, Indiana 46285, US HQ
1876 Founded
55,860 Employees
EMA registrant Type
Company details
Status
Public
HQ
Lilly Corporate Center, Indianapolis, Indiana 46285, US
Founded
1876
Employees
55,860
Programs
107
Drugs
99
Patents
0
Intelligence · Clinical Programs

Eli Lilly and projects

21 ClinicalTrials.gov programs sponsored by Eli Lilly and.

Eli Lilly and has 21 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. 0.9% sodium chloride, GADOTERIC ACID

    Eli Lilly Co.

    Relapsing Multiple Sclerosis

    phase 2 small molecule active

    1 trial
  2. Eltrekibart, 0.9% sodium chloride

    Eli Lilly Co.

    Moderate to Severe Hidradenitis Suppurativa

    phase 2 small molecule active

    1 trial
  3. Flortaucipir, Placebo to match LY3372689

    Eli Lilly Co.

    Alzheimer Disease

    phase 2 small molecule active

    1 trial
  4. I3Y-MC-JPCS

    Eli Lilly Co.

    Relapsed/Refractory Solid Tumors

    phase 2 small molecule active

    1 trial
  5. I3Y-MC-JPEH

    Eli Lilly Co.

    Glioma

    phase 2 small molecule active

    1 trial
  6. I5T-MC-AACI

    Eli Lilly Co.

    Alzheimer Disease

    phase 2 small molecule active

    1 trial
  7. I7P-MC-DSAG

    Eli Lilly Co.

    Ulcerative Colitis

    phase 2 small molecule active

    1 trial
  8. I8F-MC-GPIG

    Eli Lilly Co.

    Chronic Kidney Disease, CKD, Obesity, Overweight, T2D, Type 2 Diabetes

    phase 2 small molecule active

    1 trial
  9. J1I-MC-GZBU

    Eli Lilly Co.

    Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes

    phase 2 small molecule active

    1 trial
  10. J1R-MC-GZFD

    Eli Lilly Co.

    Type 2 Diabetes

    phase 2 small molecule active

    1 trial
  11. J1S-MC-JP04

    Eli Lilly Co.

    Ewings Sarcoma

    phase 2 small molecule active

    1 trial
  12. J2R-MC-YAAD

    Eli Lilly Co.

    Nausea, Drug-Related Side Effects and Adverse Reactions, Vomiting, Neoplasms

    phase 2 small molecule active

    1 trial
  13. J2S-MC-GZMR

    Eli Lilly Co.

    Asthma

    phase 2 small molecule active

    1 trial
  14. J6E-MC-KWAN

    Eli Lilly Co.

    Ulcerative Colitis

    phase 2 small molecule active

    1 trial
  15. LOXO-RAS-20001

    Eli Lilly Co.

    KRAS G12C-Mutant Advanced Solid Tumors

    phase 2 small molecule active

    1 trial
  16. LY2875358, ERLOTINIB

    Eli Lilly Co.

    Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial
  17. Pirtobrutinib, Placebo tablets

    Eli Lilly Co.

    Immune Thrombocytopenia

    phase 2 small molecule active

    1 trial
  18. Placebo to match LY3540378

    Eli Lilly Co.

    Heart Failure with Preserved Ejection Fraction, Heart Failure

    phase 2 small molecule active

    1 trial
  19. Placebo to match LY3556050

    Eli Lilly Co.

    Diabetic Peripheral Neuropathy

    phase 2 small molecule active

    1 trial
  20. Placebo to match LY3848575

    Eli Lilly Co.

    Neuropathic Pain; Distal Sensory Polyneuropathy

    phase 2 small molecule active

    1 trial
  21. Verzenios 50 mg film-coated tablets, TAMOXIFEN

    Eli Lilly Co.

    Metastatic Breast Cancer

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does Eli Lilly and have?

21 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.